bile duct cancer
Foundation Medicine, Relay Therapeutics to Develop FoundationOne CDx for FGFR2 Inhibitor
The companion diagnostic would be used to identify patients with FGFR2 fusions and select rearrangements in cholangiocarcinoma.
FDA Approves Bile Duct Cancer Drug from Helsinn, BridgeBio Pharma With Foundation Medicine CDx
Truseltiq is a new option for FGFR2 fusion-positive, locally advanced, or metastatic cholangiocarcinoma patients who have received prior treatment.
Incyte's Pemazyre, Foundation Medicine CDx Get FDA Approval for FGFR2-Mutated Bile Duct Cancer
The FDA approved the drug based on data on response rate but continued approval is contingent on the results of a randomized study showing a PFS and OS advantage.
Foundation Medicine, QED Therapeutics to Develop CDx for Bile Duct Cancer
The CDx, which will include the detection of activating FGFR2 fusions, is expected to be incorporated into Foundation Medicine's FDA-approved FoundationOne CDx assay.
Foundation Medicine, Incyte Partner on CDx Development
The companies initially expect to incorporate a CDx for Incyte's pemigatinib into Foundation Medicine's existing FDA-approved assay, FoundationOne CDx.